Concurrent pembrolizumab and RT (n = 21)

CharacteristicMedian (range) or n (%)
Patient characteristic
 Female7 (33%)
 Male14 (67%)
Age at diagnosis of BM, y67 (32-84)
Melanoma-specific GPA score3 (1-4)
Karnofsky performance status90 (80-90)
Median no. of BM treated w/SRS1.5 (1-5)
Median BM diameter (maximum axial), cm1.0 (0.2 - 2.4)
No. with non-brain metastases19/21
No. with prior systemic therapy13/21
Ipilimumab10/13
No. with BRAF directed therapy5/21
No. with elevated LDH3/12
Treatment characteristic
 No. with single fraction SRS11 (52%)
21 Gy, # lesions19
20 Gy, # lesions1
18 Gy, # lesions3
No. with post-op RT (5 treatments)7 (33%)
No. with whole brain RT3 (14%)
Pembrolizumab dosage
2 mg/kg18 (86%)
10 mg/kg3 (14%)
No. of pembro doses6.5 (1-38)